| Efficacy and Safety of Quetiapine Fumarate Sustained Release (SEROQUEL SR) in the Treatment of Major Depressive Disorders (NCT00326144) | AstraZeneca | 2006-04-01 |
| Safety & Efficacy Study of Quetiapine Fumarate (SEROQUEL®) vs. Placebo and Active Control in Major Depressive Disorder (NCT00321490) | AstraZeneca | 2006-04-01 |
| Safety and Efficacy Study to Determine Anti-Asthmatic Effect of Esomeprazole Magnesium; Nexium Reflux Asthma (NCT00317044) | AstraZeneca | 2006-04-01 |
| Study of Zoladex Given Every 12 Weeks Versus Given Every Month in Advanced Breast Cancer (ABC) Pre-menopausal Women (NCT00322348) | AstraZeneca | 2006-04-01 |
| A Clinical Trial to Compare Efficacy and Tolerability of Fulvestrant 250mg, 250mg (Plus 250mg Loading Regimen) and 500mg (NCT00305448) | AstraZeneca | 2006-03-01 |
| CP-675,206 Versus Either Dacarbazine Or Temozolomide In Patients Without Prior Therapy (NCT00257205) | AstraZeneca | 2006-03-01 |
| Safety and Efficacy Maintenance Study of Quetiapine SR to Treat GAD Patients. (NCT00314210) | AstraZeneca | 2006-03-01 |
| Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease (COPD): The HERMES Study (BY217/M2-125) (NCT00297115) | AstraZeneca | 2006-03-01 |
| Efficacy of SEROQUEL in Selective Serotonin Reuptake Inhibitors (SSRI)-Resistant Major Depressive Disorder (NCT00733668) | AstraZeneca | 2006-03-01 |
| Efficacy and Safety Study of Esomeprazole 20mg qd vs Ranitidine 150mg Bid in Patients With an NSAID-induced Gastric Ulcer (NCT00401752) | AstraZeneca | 2006-03-01 |
| SYMBICORT® in the Treatment of COPD (NCT00564499) | AstraZeneca | 2006-03-01 |
| Evaluation of Atacand® (Candesartan) in Daily Medical Practice (NCT00837720) | AstraZeneca | 2006-03-01 |
| Phase I Study of ZD4054 (Zibotentan) and Docetaxel in Patients With Metastatic HRPC (NCT00314782) | AstraZeneca | 2006-03-01 |
| A Study Assessing Saxagliptin Treatment in Type 2 Diabetic Subjects Who Are Not Controlled With TZD Therapy Alone (NCT00295633) | AstraZeneca | 2006-03-01 |
| First Line IRESSA™ Versus Carboplatin/Paclitaxel in Asia (NCT00322452) | AstraZeneca | 2006-03-01 |
| Safety and Efficacy of Ciclesonide in Pediatric Patients (6 to 11 Years of Age) With Seasonal Allergic Rhinitis (BY9010/M1-417) (NCT00305487) | AstraZeneca | 2006-03-01 |
| First-line Treatment for Adenocarcinoma Patients With Epidermal Growth Factor Receptor (EGFR) Mutation (NCT00344773) | AstraZeneca | 2006-03-01 |
| Renal Impairment in Type 2 Diabetic Subjects (NCT00554450) | AstraZeneca | 2006-03-01 |
| A Clinical Trial to Compare Efficacy and Tolerability of Faslodex With Arimidex in Patients With Advanced Breast Cancer (NCT00274469) | AstraZeneca | 2006-02-06 |
| Comparative Study of Oestradiol Suppression: Zoladex 10.8mg/3 Month vs. 3.6mg/Month in ER +ve EBC Pre-menopausal Patients (NCT00303524) | AstraZeneca | 2006-02-01 |
| Prospective Evaluation of Proteinuria and Renal Function in Non-diabetic Patients With Progressive Renal Disease (NCT00296400) | AstraZeneca | 2006-02-01 |
| Antibiotic Therapy for Hospital-Acquired Infections in ICU Patients (NCT00543894) | AstraZeneca | 2006-02-01 |
| Improved Quality of the Treatment and Increased Compliance in Asthmatics Through the Dialog Tool Soren - Between Patient and Caregiver (NCT00272727) | AstraZeneca | 2006-02-01 |
| A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Tolerability of Exenatide in Adolescent Subjects With Type 2 Diabetes Mellitus (NCT00254254) | AstraZeneca | 2006-02-01 |
| Effect of Ciclesonide on Quality of Life in Patients With Moderate Persistent Asthma (21 to 65 y) (BY9010/AR-101) (NCT00305461) | AstraZeneca | 2006-02-01 |
| Symbicort in Chronic Obstruktive Pulmonary Disease (NCT00612976) | AstraZeneca | 2006-02-01 |
| Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease (COPD): The AURA Study (BY217/M2-124) (NCT00297102) | AstraZeneca | 2006-02-01 |
| Prospective Evaluation of Proteinuria and Renal Function in Diabetic Patients With Progressive Renal Disease (NCT00296374) | AstraZeneca | 2006-02-01 |
| Observational to Investigate the Efficacy of CRESTOR 5mg in Reaching LDL-C Target Goals in Patients Who Are at High Risk for a Cardiovascular Event (NCT00347217) | AstraZeneca | 2006-02-01 |
| Faslodex in McCune-Albright Syndrome (NCT00278915) | AstraZeneca | 2006-01-31 |
| Maintenance ZD1839 (IRESSA®) Following Completion of Front Line, Platinum-Based, Double Chemotherapy in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer (NCT00090675) | AstraZeneca | 2006-01-01 |
| Second Line ColoRectal Cancer Therapy in Combination With Combination of FOL- Folinic Acid(Leucovorin), F - Fluorouracil and OX - Oxaliplatin (FOLFOX) (NCT00278889) | AstraZeneca | 2006-01-01 |
| Pan-European Survey on the Under Treatment of Hypercholesterolemia (NCT00542867) | AstraZeneca | 2006-01-01 |
| Trans GERD: Efficacy and Tolerability of Esomeprazol in Patients Under Ordinary Medical Care Conditions (NCT00612027) | AstraZeneca | 2006-01-01 |
| Efficacy and Safety of Quetiapine Fumarate (SEROQUEL®) in the Treatment of Alcohol Dependency in Patients With Bipolar Disorder (NCT00114686) | AstraZeneca | 2006-01-01 |
| Safety and Efficacy of Exenatide in Patients With Type 2 Diabetes Using Metformin or Sulfonylureas and Metformin (NCT00324363) | AstraZeneca | 2006-01-01 |
| An Open Label pH Comparison of Esomeprazole and Lansoprazole in Barrett's Esophagus Patients (NCT00352261) | AstraZeneca | 2006-01-01 |
| Esomeprazole And Symptomatic Response In Patients With Or Without An Elevated Risk For Non-Steroidal Anti-Inflammatory Drug (NSAID)-Associated GI Damage (NCT00524329) | AstraZeneca | 2006-01-01 |
| Effects in The ApoB/ApoA-I Ratio Using Rosuvastatin and Atorvastatin in Patients With Acute Coronary Syndrome (NCT00296387) | AstraZeneca | 2006-01-01 |
| Does Tailored Education in Asthma Care Help Improve Patient Satisfaction, Adherence, and Quality of Life (TEACH) Trial (NCT00687310) | AstraZeneca | 2005-12-01 |
| The Effects on Blood Pressure Control, Pulse Wave Velocity, as Well as Safety and Tolerability of Felodipine Sustained Release in Chinese Patients. (NCT02336607) | AstraZeneca | 2005-12-01 |
| The Effects of AZD2171 in Patients With Non-Small Cell Lung Cancer or Head & Neck Cancer (NCT00243347) | AstraZeneca | 2005-12-01 |
| Esomeprazole in PPI Failures - IMPROVE (NCT00272701) | AstraZeneca | 2005-12-01 |
| Quetiapine Fumarate as Monotherapy in the Maintenance Treatment of Patients With Major Depressive Disorder (NCT00278941) | AstraZeneca | 2005-12-01 |
| Study of CP-675,206 in Refractory Melanoma (NCT00254579) | AstraZeneca | 2005-12-01 |
| A Trial of BMS-512148 in Patients With Type 2 Diabetes Mellitus (NCT00263276) | AstraZeneca | 2005-12-01 |
| A Comparison of Symbicort® Single Inhaler Therapy and Conventional Best Practice for the Treatment of Persistent Asthma (NCT00628758) | AstraZeneca | 2005-12-01 |
| Use Of Esomeprazole In Postoperative Bariatric Surgery Patients Users And Non-Users Of Nonsteroidal Anti-Inflammatory Drugs (NSAIDS) (NCT00608712) | AstraZeneca | 2005-11-01 |
| Efficacy and Safety of Ciclesonide in Preschool Children With Asthma (2 to 6 Years) (BY9010/M1-207) (NCT00163449) | AstraZeneca | 2005-11-01 |
| Faslodex Advanced Breast Cancer Local Chinese Study (NCT00327769) | AstraZeneca | 2005-11-01 |
| Phase I Orally Administered 14C-AZD2171 in Patients With Solid Metastatic Tumors (NCT00503412) | AstraZeneca | 2005-11-01 |
| Survey in Post-menopausal Women Followed up After Treatment With Anastrozole as Adjuvant Therapy (NCT00542594) | AstraZeneca | 2005-11-01 |
| The Effects of Exenatide on Oral Contraceptive Pharmacokinetics in Healthy Females (NCT00254800) | AstraZeneca | 2005-11-01 |
| Safety & Efficacy of Symbicort® Turbuhaler® (1, 2, and 4 x 160/4.5 µg Twice Daily) in Japanese Patients With Asthma (NCT00255255) | AstraZeneca | 2005-11-01 |
| Safety and Tolerability of Ciclesonide Nasal Spray in Patients With Perennial Allergic Rhinitis (2-5 Years Old) (BY9010/M1-416) (NCT00261287) | AstraZeneca | 2005-11-01 |
| Study to Investigate the Management of Hypertension and Efficacy of AZD2171 in Patients With Advanced Solid Tumours (NCT00264004) | AstraZeneca | 2005-11-01 |
| Efficacy & Safety of Symbicort® TURBUHALER® 160/4.5 µg Twice Daily & Pulmicort® TURBUHALER® 200 µg Twice Daily + Theolong® Tablet 200 mg Twice Daily in Japanese Asthmatic Patients (NCT00252785) | AstraZeneca | 2005-10-01 |
| Examine National Characteristics & Outcome Measures of GERD Patients Using the PPI Acid Suppression Symptom (PASS) Test for Response (NCT00392002) | AstraZeneca | 2005-10-01 |
| Rosuvastatin in the Long-term Treatment of Hypercholesterolaemic Subjects With Coronary Heart Disease (NCT00329160) | AstraZeneca | 2005-10-01 |
| An Open-Label Study of Once-Daily Oral Administration of Esomeprazole 40 mg in Patients With Symptoms of Gastroesophageal Reflux Disease (GERD) (NCT00242736) | AstraZeneca | 2005-10-01 |
| A Study Evaluating the Efficacy and Safety of Adding Symlin® to Lantus® (Insulin Glargine) in Subjects With Type 2 Diabetes (NCT00240253) | AstraZeneca | 2005-10-01 |
| GALLEX 4 - Long-Term Extension Study to Evaluate Tesaglitazar Therapy in Patients With Type 2 Diabetes (NCT00300105) | AstraZeneca | 2005-10-01 |
| A Study to Prevent Rebleeding After Initial Successful Primary Endoscopic Haemostasis of a Bleeding Peptic Ulcer (NCT00251979) | AstraZeneca | 2005-10-01 |
| Efficacy and Safety of Metoprolol Succinate Prolonged-Release Tablet in Patients With Mild to Moderate Hypertension (NCT00861016) | AstraZeneca | 2005-10-01 |
| Effect of Exenatide on 24-Hour Blood Glucose Profile Compared With Placebo in Patients With Type 2 Diabetes (NCT00241423) | AstraZeneca | 2005-10-01 |
| A Phase I Open Label Dose Escalation Study for the Safety and Tolerability of AZD2171 in Solid Tumors in Japan (NCT00503477) | AstraZeneca | 2005-10-01 |
| C-Reactive Protein (CRP) in Obese Diabetic Women (NCT00262548) | AstraZeneca | 2005-10-01 |
| An Evaluation of Exenatide and Rosiglitazone in Subjects With Type 2 Diabetes Mellitus (NCT00135330) | AstraZeneca | 2005-10-01 |
| Real Life Effectiveness in Asthma of Symbicort Single Inhaler Therapy (NCT00319306) | AstraZeneca | 2005-09-01 |
| Melagatran/Ximelagatran Versus Enoxaparin for the Prevention of Venous Thromboembolic Events (NCT00206089) | AstraZeneca | 2005-09-01 |
| Unraveling the Relation of Patient's Profile and Therapeutical Effects of Atypicals, Including Quetiapine Effect (NCT00534222) | AstraZeneca | 2005-09-01 |
| Effects of Inhaled Ciclesonide Versus Fluticasone Propionate Versus Placebo on Lower Leg Growth in Prepubertal Children With Mild Persistent Asthma (6 to 12 y) (BY9010/M1-208) (NCT00163371) | AstraZeneca | 2005-09-01 |
| Validation of RDQ Questionnaire (NCT00291746) | AstraZeneca | 2005-09-01 |
| Study of 24-hour Intragastric pH Profiles of Esomeprazole 40 mg and Lansoprazole 30 mg in Healthy Volunteer Subjects (NCT00230516) | AstraZeneca | 2005-09-01 |
| Efficacy and Safety of AZD7009 in the Treatment of Atrial Fibrillation (NCT00255281) | AstraZeneca | 2005-09-01 |
| Iressa as Second Line Therapy in Advanced NSCLC-Asia (NCT00478049) | AstraZeneca | 2005-09-01 |
| German PMS Trial (AWB) to Evaluate Therapy in Reflux Disease and NSAR-Symptoms (NCT00567021) | AstraZeneca | 2005-09-01 |
| Efficacy and Safety of Ciclesonide Administered With or Without Different Spacers in Patients With Asthma (12 to 75 y) (BY9010/M1-145) (NCT00163436) | AstraZeneca | 2005-09-01 |
| Symptoms and Endoscopic Results in Consideration of Pretreatment (NCT00612404) | AstraZeneca | 2005-09-01 |
| Seroquel® Combined With Cognitive Remediation Therapy to Conventional Treatment in Patients With Schizophrenia (NCT00255515) | AstraZeneca | 2005-09-01 |
| G-PLUS (GALLANT, GALLEX and ARMOR - Post Treatment Follow-up Study) (NCT00255645) | AstraZeneca | 2005-09-01 |
| Symbicort in Chronic Obstructive Pulmonary Disease (NCT00611520) | AstraZeneca | 2005-09-01 |
| Comparison Between Symbicort® and Prednisolone in COPD (NCT00259779) | AstraZeneca | 2005-09-01 |
| An Observational Study Evaluating SYMLIN® (Pramlintide Acetate) Injection Use in Insulin Using Patients With Type 2 and Type 1 Diabetes (NCT00229658) | AstraZeneca | 2005-09-01 |
| A Study to Examine the Long Term Effect of Pramlintide on Body Weight and Its Safety and Tolerability in Obese Subjects (NCT00189514) | AstraZeneca | 2005-09-01 |
| Study Assessing Saxagliptin Treatment In Type 2 Diabetic Subjects Who Are Not Controlled With Metformin Alone (NCT00121667) | AstraZeneca | 2005-08-01 |
| ARAMIS: Actions of tesaglitazaR on fAt Metabolism and Insulin Sensitivity (NCT00263965) | AstraZeneca | 2005-08-01 |
| Korean Rosuvastatin Effectiveness Study in Nondiabetic Metabolic Syndrome (NCT00335699) | AstraZeneca | 2005-08-01 |
| Efficacy and Safety of Oral Roflumilast Taken Once Daily in Patients Older Than 40 Years With Chronic Obstructive Pulmonary Disease (BY217/M2-119) (NCT00242320) | AstraZeneca | 2005-08-01 |
| Seroquel in Bipolar Depression Versus Lithium (NCT00206141) | AstraZeneca | 2005-08-01 |
| Adherence in Adolescents and Children Treated on Quetiapine (NCT00680888) | AstraZeneca | 2005-08-01 |
| Efficacy and Safety of Seroquel and Lithium as Monotherapy in Acute Mania Treatment in Bipolar Disorder Patients (NCT00448578) | AstraZeneca | 2005-08-01 |
| A Study to Assess the Safety and Pharmacokinetics of an Inhibitor of Poly ADP-Ribose Polymerase-1 (PARP) (NCT00516373) | AstraZeneca | 2005-07-11 |
| Safety and Tolerability of Ciclesonide and Formoterol Fumarate Inhaled Once Daily in Patients With Asthma (18 to 75 y) (BY9010/M1-506) (NCT00314509) | AstraZeneca | 2005-07-01 |
| STYLE - Symbicort Single Inhaler Therapy vs Conventional Therapy in Treatment of Persistent Asthma (NCT00252824) | AstraZeneca | 2005-07-01 |
| Saxagliptin Treatment in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise (NCT00121641) | AstraZeneca | 2005-07-01 |
| Seroquel in Acute Mania: Study to Investigate if Valproate Add-On Therapy is Superior to Quetiapine Monotherapy in Acutely Manic Patients (NCT00139074) | AstraZeneca | 2005-07-01 |
| Study Evaluating Gefitinib (IRESSA®) in Subjects With Solid Malignancies That Are Locally Advanced, Recurrent or Metastatic (NCT00127829) | AstraZeneca | 2005-07-01 |
| Faslodex Observations During Regular Use by Advanced Mammacarcinoma Patients (NCT00241462) | AstraZeneca | 2005-06-01 |
| Open Label Arimidex in Gynecomastia (NCT00241436) | AstraZeneca | 2005-06-01 |